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Finding the root of renal fibrosis
Tubulointerstitial fi brosis is the common pathology pathway 
through which chronic kidney diseases progress to end-
stage renal failure. Epithelial-to-mesenchymal transition 
(EMT) seems to play a central role in this process. Two 
recent publications in the American Journal of Pathology 
contribute to the unraveling of the cell biology of EMT. 
Masszi and colleagues used a cell culture model whereby 
the integrity of cell contact was found to be a critical 
regulator of transforming growth factor-β1-induced EMT. 
Th ey showed a β-catenin-dependent two-hit mechanism 
in which both an initial epithelial injury and transforming 
growth factor-β1 were required for EMT. Slattery et al. used 
a human proximal tubular cell line to provide novel insights 
into how EMT plays a role in cyclosporine-A-induced renal 
fi brosis. (Am J Pathol 2004; 165: 1955–1967; Am J Pathol 
2005; 167: 395–407)
Marc De Broe
The role of chemokines in renal 
cancer
Renal-cell carcinoma (RCC) ranks as the tenth leading 
cause of cancer death. Th e aggressiveness of the tumor 
is attributed, in part, to a high incidence of inactivation 
of the tumor suppressor gene von Hippel-Lindau, which 
results in enhanced expression of proangiogenic factors. 
In addition to growth factors, such as vascular endothelial 
growth factor, chemokines can contribute to tumor 
progression. ELR+ (Glu-Leu-Arg+) CXC chemokine family 
members promote angiogenesis in tumors through the 
common receptor CXCR2. A new study hypothesizes 
that the CXCR2/CXCR2 ligand biological axis represents 
a mechanism by which RCC cells promote angiogenesis 
and facilitate tumor growth. Th e authors examined tumor 
biopsies and plasma of patients with metastatic RCC for 
levels of CXCR2 ligands, and RCC tumor biopsies for the 
expression of CXCR2. Th e proangiogenic CXCR2 ligands 
CXCL1, CXCL3, CXCL5, and CXCL8, as well as vascular 
endothelial growth factor, were elevated in the plasma of 
these patients and were found within the tumors. CXCR2 
was found on endothelial cells within the tumors. To assess 
the role of ELR+ CXC chemokines in RCC, the authors 
then used a model of syngeneic RCC. CXCR2 ligand and 
vascular endothelial growth factor expression temporally 
increased in direct correlation with tumor growth in 
CXCR2+/+ mice. However, there was a marked reduction 
of tumor growth in CXCR2–/– mice, which correlated with 
decreased angiogenesis and increased tumor necrosis. 
Furthermore, in the absence of CXCR2, orthotopic RCC 
tumors demonstrated a reduced potential to metastasize to 
the lungs. Th ese data support the notion that CXCR2 and its 
ligands are important components of RCC tumor-associated 
angiogenesis and tumorigenesis, and they indicate potential 
additive therapeutic approaches to RCC therapy. (J Immunol 
2005; 175: 5351–5357)
Detlef Schlöndorff
Treatment of lupus via a novel 
mechanism
New research provides strong evidence that toll-like receptors 
(TLRs) are involved in the pathophysiology of systemic lupus 
erythematosus and renal involvement. TLRs are pattern 
recognition receptors of the innate immune system that 
recognize a broad range of infectious agent-related molecules. 
Of ten identifi ed human TLRs, four recognize nucleic acids 
and initiate a rapid response to the infection. But they also 
initiate an infl ammatory response via generation of mediators 
of infl ammation such as eicosanoids, and chemokines and 
cytokines, including interferon-α (IFN-α). Raised serum 
levels of IFN-α, which have been observed in systemic 
lupus erythematosus patients, correlate with both disease 
activity and severity. Th e source of IFN-α is still unclear, 
but increasing evidence suggests the critical involvement of 
activated plasmacytoid pre-dendritic cells. In systemic lupus 
erythematosus patients, DNA and RNA viruses, as well as 
immune complexes, can stimulate production of IFN-α. 
Th e authors of a new study have developed three series of 
oligonucleotide-based inhibitors of TLR signaling. Th ey show 
that mammalian DNA and RNA are potent self-antigens for 
TLR signaling and induce IFN-α production, suggesting 
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that TLRs may have a critical role promoting systemic lupus 
erythematosus. Th ese inhibitors of TLR signaling thus 
represent novel therapeutic agents with the potential for 
treating lupus. (J Exp Med 2005; 202: 1131–1139)
Detlef Schlöndorff
Balloon-expandable stents treat 
renal artery stenosis
Atherosclerotic renal artery stenosis, a common disorder, 
is increasingly being treated by percutaneous angioplasty 
with stent placement. Yet few serious long-term studies of 
the effi  cacy of this mode of therapy exist. Now, Rocha-Singh 
et al. report the fi ndings of a prospective, non-randomized, 
multicenter study in which the condition was treated with 
balloon-expandable stents. Th e stents were implanted 
in 208 patients, most of whom had ostial lesions. None 
of the patients had responded to standard percutaneous 
angioplasty. Response was defi ned in the study as a residual 
stenosis of greater than 50% persistent pressure gradient 
or dissection. Clinical examination and angiography or 
duplex ultrasonography were performed 9 months later. 
Immediately aft er the procedure, the success rate was 80%. 
Th e recurrence rate of stenosis was 17% at 9 months. Blood 
pressure decreased from 168/82 mm Hg to 149/77 mm Hg 
at 9 months and remained at a similar level 24 months aft er 
the procedure. Th ere was a small but statistically signifi cant 
reduction in the percentage of patients who were taking 
antihypertensive medications from 2.8% to 2.3% over 
the period of observation. Th ere was no change in serum 
creatinine levels. A total of 20% of patients had adverse 
events. Th ese results provide evidence for safety and effi  cacy 
of balloon-expandable stents in treating patients with 
atherosclerotic renal artery stenosis who do not respond to 
standard therapy. (J Am Coll Cardiol 2005; 46: 776–783)
Qais Al-Awqati
The culprit in a rare fetal kidney 
disease
Researchers from France have identifi ed the cause of a rare 
and fatal fetal kidney disease called autosomal recessive 
tubular dysgenesis. Th e condition, marked by lack of 
diff erentiated proximal tubules in the kidney, was found in 
11 individuals from nine families either in vivo or at birth. 
All the children had mutations in several components of 
their renin–angiotensin systems: some had homozygous 
mutations, whereas others had compound heterozygous 
mutations. Th e mutations, which were found in the genes that 
encode renin, angiotensin, angiotensin-converting enzyme, 
or angiotensin II receptor type 1, inactivated their renin–
angiotensin systems. Th is inactivity probably caused low 
perfusion pressure in the kidney, resulting in symptomatic 
renal lesions. Many of the renal lesions were severe enough to 
cause early anuria and death. Th ese fi ndings suggest that the 
renin–angiotensin system plays a crucial role in fetal kidney 
development. And although autosomal recessive tubular 
dysgenesis is rare, its link to genetic mutations suggests that it 
may be more common than previously thought. Th e authors 
suggest that the condition be considered in all fetuses with 
anuria that show normal kidney function by sonogram. 
Pre-emptive consideration will allow for early detection 
and diagnosis and genetic counseling. (Nat Genet 2005; 37: 
964–968)
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